HLA genotype and response to nivolumab therapy in relapsed refractory primary mediastinal B-cell lymphoma

Curr Res Transl Med. 2019 Feb;67(1):31-33. doi: 10.1016/j.retram.2018.11.001. Epub 2018 Nov 14.
No abstract available

Keywords: HLA; PD-1 inhibitor; Primary mediastinal B-cell lymphoma.

Publication types

  • Case Reports
  • Letter

MeSH terms

  • Adult
  • Drug Resistance, Neoplasm* / drug effects
  • Drug Resistance, Neoplasm* / genetics
  • Female
  • Genotype
  • HLA Antigens / genetics*
  • Humans
  • Lymphoma, B-Cell* / drug therapy
  • Lymphoma, B-Cell* / genetics
  • Lymphoma, B-Cell* / pathology
  • Mediastinal Neoplasms* / drug therapy
  • Mediastinal Neoplasms* / genetics
  • Mediastinal Neoplasms* / pathology
  • Nivolumab / therapeutic use*
  • Pharmacogenomic Testing
  • Recurrence
  • Treatment Outcome

Substances

  • HLA Antigens
  • Nivolumab